The text has been copied to the clipboard
Donor-specific antibodies in liver transplantation.
Journal article

Donor-specific antibodies in liver transplantation.

  • Vionnet J Institute of Liver Studies, King's College Hospital, London, United Kingdom; Transplantation Centre, University Hospital of Lausanne, Lausanne, Switzerland; Service of Gastroenterology and Hepatology, University Hospital of Lausanne, Lausanne, Switzerland. Electronic address: Julien.Vionnet@kcl.ac.uk.
  • Sempoux C Institute of Pathology, University Hospital of Lausanne, Lausanne, Switzerland.
  • Pascual M Transplantation Centre, University Hospital of Lausanne, Lausanne, Switzerland.
  • Sánchez-Fueyo A Institute of Liver Studies, King's College Hospital, London, United Kingdom.
  • Colmenero J Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.
  • 2019-12-08
Published in:
  • Gastroenterologia y hepatologia. - 2020
English Despite unique immunoregulatory properties pointing toward tolerance, the liver allograft can be negatively impacted by humoral alloreactivity, with immediate as well as long-term harmful consequences. With regard to the unmet need of long-term outcomes improvement after liver transplantation, donor-specific antibodies have recently been the matter of intense study in this context. We review here recent advances regarding the understanding of the impact of preformed as well as de novo anti-human leukocyte antigen donor-specific antibodies in liver transplantation and discuss potential strategies to overcome this problem.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/44690
Export to…

Statistics

Document views: 53 File downloads: